Background: Antiangiogenic treatment has been explored in few patients with hemangioblastoma after failure of surgery and radiotherapy. Case Report: We present the first histopathological follow-up study of a bevacizumab-responsive hemangioblastoma that eventually progressed. For a period of 12 months, therapy with bevacizumab achieved a clinical response and radiological stabilization in a patient with progressive multifocal central nervous system (CNS) hemangioblastoma. Subsequently, selected tumor sites showed radiological progression, in particular, the formation of an intramedullary lesion of the initially predominantly leptomeningeal disease. Histology showed diffuse dural invasion by the hemangioblastoma accompanied with a relatively reduced cell density compared to the preserved vessel structures. Conclusion: The pattern of progression upon vascular endothelial growth factor (VEGF)-targeting antiangiogenic treatment in hemangioblastoma may involve increased tumor invasiveness.

Journal Section:
Novel Insights from Clinical Practice
Keywords:
Bevacizumab, VEGF, Hemangioblastoma, Angiogenesis
1.
Takai K, Taniguchi M, Takahashi H, Usui M, Saito N: Comparative analysis of spinal hemangioblastomas in sporadic disease and von Hippel-Lindau syndrome. Neurol Med Chir (Tokyo) 2010; 50:560-567.
[PubMed]
https://doi.org/10.2176/nmc.50.560
2.
Safran M, Kaelin WG Jr: HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003;111:779-783.
[PubMed]
https://doi.org/10.1172/JCI200318181
3.
Vortmeyer AO, Falke EA, Gläsker S, Li J, Oldfield EH: Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol 2013;125:333-350.
[PubMed]
https://doi.org/10.1007/s00401-013-1091-z
4.
Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 1993;194:749-755.
[PubMed]
https://doi.org/10.1006/bbrc.1993.1885
5.
Böhling T, Hatva E, Kujala M, Claesson-Welsh L, Alitalo K, Haltia M: Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 1996;55:522-527.
[PubMed]
6.
Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M: Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie 2012;35:443-445.
[PubMed]
https://doi.org/10.1159/000341075
7.
Omar AI: Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report. J Med Case Rep 2012;6:238.
[PubMed]
https://doi.org/10.1186/1752-1947-6-238
8.
Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF: Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 2011;22:2661-2666.
[PubMed]
https://doi.org/10.1093/annonc/mdr011
9.
9 Bottsford-Miller JN, Coleman RL, Sood AK: Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012;30:4026-4034.
[PubMed]
https://doi.org/10.1200/JCO.2012.41.9242
10.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
[PubMed]
https://doi.org/10.1016/j.ccr.2009.01.027
11.
de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-242.
[PubMed]
https://doi.org/10.1093/neuonc/nop027
© 2014 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.